Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance
10.11904/j.issn.1002-3070.2024.01.011
- VernacularTitle:lncRNA CASC2与肿瘤化疗耐药实验研究进展
- Author:
Hongyue SHANG
1
;
Manman YAO
;
Yueting LU
;
Dixian WANG
;
Qian ZHAO
;
Tiejun LIU
Author Information
1. 河北医科大学第四医院口腔科(石家庄 050011)
- Keywords:
long non-coding RNA;
Cancer susceptibility candidate 2;
Chemotherapy;
Drug resistance;
Tumor
- From:
Practical Oncology Journal
2024;38(1):67-70
- CountryChina
- Language:Chinese
-
Abstract:
Malignant tumors have become the main cause of human death.With the prolonged use of chemotherapeutic drugs during the treatment process,tumor cell resistance is also constantly increasing.long non-coding RNA(lncRNA)is an important mem-ber of the non-coding RNA family.Cancer susceptibility candidate 2(CASC2)is a type of long non-coding RNA,high expression of CASC2 can inhibit tumor cell development and reduce drug resistance of tumor cells by promoting apoptosis,regulating signaling path-ways,participating in cellular transmission pathways,competitively binding of miRNA,and changing the protein structure or functional status.This article will provide a comprehensive review of the regulatory effects and mechanism of lncRNA CASC2 on chemotherapy resistance in malignant tumors.
